10 Analysts Assess Genmab: What You Need To Know
Analysts’ ratings for Genmab (NASDAQ:GMAB) over the last quarter vary from bullish to bearish, as provided by 10…
Genmab, BioNTech Announced Data At ASCO, Showing Investigational Acasunlimab In Combination With Pembrolizumab Resulted In 12-month Overall Survival Rate of 69% In Patients With Previously Treated Metastatic Non-small Cell Lung Cancer
Genmab A/S (NASDAQ:GMAB) and BioNTech SE (NASDAQ:BNTX) todayannounced initial data from the Phase 2 GCT1046-04 trial (NCT05117242) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also
Intuit, Workday And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 50 points on Friday. Shares…
What 9 Analyst Ratings Have To Say About Genmab
Genmab (NASDAQ:GMAB) has been analyzed by 9 analysts in the last three months, revealing a diverse range of…
Decoding 9 Analyst Evaluations For Genmab
Throughout the last three months, 9 analysts have evaluated Genmab (NASDAQ:GMAB), offering a diverse set of opinions from…
ProfoundBio discovers the joys of having a wealthy owner
Key Takeaways:
Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion
The deal is the fourth acquisition of a China-related innovative drugmaker by a foreign company in the last four months
By Doug Young
4 Analysts Assess Genmab: What You Need To Know
4 analysts have shared their evaluations of Genmab (NASDAQ:GMAB) during the recent three months, expressing a mix of…
Genmab Announces Initiation Of Share Buy-Back Program Of Up To 190,000 Shares; Will Start On February 15, 2024, And End On March 15, 2024
Company AnnouncementRepurchase of up to 190,000 shares Honoring commitments under our Restricted Stock Unit program Completion expected on March 15, 2024 COPENHAGEN, Denmark; February 14, 2024 –
Earnings Outlook For Genmab
Genmab (NASDAQ:GMAB) is set to give its latest quarterly earnings report on Wednesday, 2024-02-14. Here’s what investors need…
Cracking The Code: Understanding Analyst Reviews For Genmab
In the last three months, 5 analysts have published ratings on Genmab (NASDAQ:GMAB), offering a diverse range of…